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EDITORIAL
Erythropoietin: A potential remedy for renal tubular injury?
Depending upon its extent, renal hypoxic or toxic in-
sults lead either to frank tubular necrosis, programmed
cell death (apoptosis), or sublethal reversible cell injury.
Both programmed cell death and sublethal injury repair
are energy-dependent processes, associated with the ac-
tivation of numerous cellular reactions. This response ul-
timately ends with apoptotic death for some cells, and
in adaptive preconditioning of the remaining viable tis-
sue to withstand recurrent injury. Some of the energy
consuming reparative responses, such as the activation
of poly-(ADP-ribose) polymerase for the restoration of
DNA breaks, may intensify cellular ATP depletion and
oxygen debt and might paradoxically accentuate tissue
damage [1]. This underscores the importance of coacti-
vation of other factors required for a balanced cellular
response.
Many of those reactions to hypoxic stress are
initiated by the so-called hypoxia-inducible factors
(HIF). HIF are heterodimers consisting of constitu-
tively expressed b-subunit and an oxygen-dependent and
transcriptionally active a-subunit. HIF-a subunits are
regulated by oxygen-dependent proteolysis. Recently,
special prolyl-hydroxylases were discovered to act as cell
oxygen sensors and as key enzymes of HIF-a degrada-
tion. Under low cellular oxygen tension prolyl hydrox-
ylase activity is reduced, HIF-a accumulates within the
cytoplasm, and binds to HIF-b , which allows HIF-a to
translocate into the nucleus. The ab heterodimer binds to
nuclear “hypoxia-responsive elements,” leading to tran-
scriptional activation of a wide set of genes, including
erythropoietin (EPO). HIF-target genes are responsible
for changes in cell cycle, glucose uptake, metabolism,
and scavenging of free radicals. Genes controlling the
expression of various heat-shock proteins, of angiogene-
sis, and vascular tone are also dominated by HIF [2, 3].
Up-regulation of these genes is in large part responsi-
ble for the well-known phenomenon of delayed hypoxic
preconditioning (i.e., improved tolerance to repeated hy-
poxic stress). Indeed, HIF isoforms appear in tubular, in-
terstitial, and vascular endothelial cells at the margin of
infracted regions within the kidney [4], and in the outer
and inner medulla in response to the well-characterized
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decline in regional ambient PO2, associated with the in-
hibition of prostaglandin- or nitric oxide-synthesis, or fol-
lowing the administration of radiocontrast [5].
EPO is one of the many genes activated by HIF during
the decline in ambient pO2. For years, renal peritubular
interstitial cells were identified as the principal source
of EPO, required for the physiologic control of red-cell
mass. However, EPO synthesis has recently been docu-
mented in many tissues, and most renal cell types were
found to express EPO receptors [6], underscoring a po-
tential physiologic autocrine or paracrine role for EPO
other than the regulation of erythropoiesis. Though the
significance of the ubiquitous expression of EPO under
physiologic conditions is yet to be defined, EPO seems
to modulate cellular response to stress, and to attenu-
ate apoptosis and cell necrosis in various organs, includ-
ing brain [7], retina [8], heart [9], and the kidney [6,
10, 11]. The report by Fishbane et al, presented in the
current issue of Kidney International [12], complements
these studies, demonstrating an anti-apoptotic effect of
darbepoietin-alpha, a long-acting EPO analog in cultured
mesangial and tubular cells subjected to hypoxic or toxic
stress. Renal protective effect has been documented also
in vivo. In animals subjected to cis-platinum [10] or to
ischemia-reflow injury [6, 11], EPO attenuated necrosis
and apoptosis and enhanced functional and morphologic
tubular recovery.
The mechanisms through which EPO mediates renal
ischemic tolerance are gradually being understood. Bind-
ing to the EPO receptor seems to be important, as sug-
gested by Fishbane [12]. Using the renal ischemia-reflow
model, Yang et al [11] show that EPO administration, per-
haps through the induction of heat shock protein (HSP)-
70, attenuates apoptotic signaling, and at the same time
favorably regulates various MAP kinases.
Established acute as well as chronic renal parenchymal
disease might paradoxically lead to improved medullary
oxygenation (through diminished glomerular filtration-
rate and oxygen-consumption for tubular transport
activity), that may be associated with blunted HIF ex-
pression and reduced endogenous EPO production [13,
14]. Indeed, critically ill patients have lower circulating
EPO [15]. It is conceivable that especially under such cir-
cumstances of limited EPO availability, exogenous EPO
might hasten tubular recovery during acute parenchymal
injury, and attenuate the decline in kidney function in
chronic renal disease, as has been clinically documented
[16].
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Despite these promising avenues and the established
safety of EPO administration in patients with chronic
renal failure, caution is required before an initiation of
clinical trials with EPO for acute kidney failure. Its poten-
tial to acutely affect the renal microcirculation or to pro-
duce uncontrolled angiogenesis and fibrosis under such
conditions should be explored.
Stimulation of intrinsic HIF, through its wide-range
adaptive responses, might theoretically be superior to
exogenous EPO for the amelioration of acute re-
nal parenchymal injury. However, clinically applicable
modalities to attenuate the degradation of HIF-a are cur-
rently unavailable, and a lot has yet to be learned about
the consequent cellular responses and the time required
for turning-on cell-preservative pathways.
Finally, for reasons detailed elsewhere [17], the warm
ischemia-reflow model of acute tubular necrosis used by
Fishbane [12] and Yang [11] hardly represents the hu-
man clinical syndrome of hypoxic tubular necrosis, de-
spite its convenience and reproducibility. Therefore, the
preliminary promising results with EPO should be ex-
tended first to more clinically relevant animal models. In
such animal models, improving cellular preservation or
recovery, as likely promoted by EPO, makes more sense
as a therapeutic approach than attempting to enhance
glomerular filtration, which increases metabolic require-
ments for reabsorption and intensify medullary oxygen
insufficiency.
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